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Calculated Glomerular Filtration Rate for Assessment
of Renal Function before Autologous
and Allogeneic BMT
Theresa Hahn, Song Yao, Lauren M. Dunford, Julie Thomas, James Lohr, Pradeep Arora,
Minoo Battiwalla, Shannon L. Smiley, Philip L. McCarthy, Jr.Common blood and marrow transplantation (BMT) eligibility criteria include a minimum glomerular filtra-
tion rate (GFR) that may vary by regimen intensity. GFR is often estimated by measurement of creatinine
clearance in a 24-hour urine collection (24-hr CrCl), an inconvenient and error-prone method that overes-
timates GFR. The study objectives were to determine which of 6 GFR calculations: Cockroft-Gault (CG),
modified CG (mCG), Modification of Diet in Renal Disease 1 (MDRD1), MDRD2, Jelliffe, and Wright,
consistently underestimated measured 24-hr CrCl pre-BMT. We retrospectively analyzed 98 consecutive
allogeneic (n 5 48) or autologous (n 5 50) adult BMT patients from January 2006 to April 2007. All 6 for-
mulas were significantly (P\ .001) correlated with 24-hr CrCl with R 5 0.64 (Wright), 0.63 (CG), 0.61
(mCG), 0.61 (Jelliffe), 0.54 (MDRD2), and 0.50 (MDRD1). When compared to the measured 24-hr CrCl,
MDRD2 consistently underestimated it in the highest proportion of patients (66%, P\ .001), compared
with MDRD1 (65%, P\ .001), Jelliffe (61%, P 5 NS), mCG (55%, P 5 NS), Wright (34%, P\ .001), and
CG (34%, P 5 .001). Measured 24-hr CrCl, pre-BMT serum Cr, and all 6 equations were not predictive of
renal regimen-related toxicity (RRT) post-BMT. The Wright and CG formulas are closest to, but overesti-
mate 24-hr CrCl in 66% of patients. In comparison, MDRD2 consistently underestimates 24-hr CrCl in
66%. Although MDRD2 is the most conservative formula, all 6 formulas gave reasonable estimates of GFR
and any of the 6 equations can replace the measured 24-hr CrCl. Larger analyses and transplantation of
patients with GFR\50 mL/min may better define subgroups at risk for renal RRT.
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Patients undergoing blood and marrow transplan-
tation (BMT) are at risk for several toxicities, including
renal regimen-related toxicity (RRT), because of their
exposure to high-dose chemotherapy agents and total
body irradiation (TBI) [1-4]. Assessment of organ
status (including kidney, liver, pulmonary, and cardiac
function) prior to BMT is usually required; however,
eligibility criteria vary between centers. Creatininelood andMarrowTransplantation Program,Department
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6/j.bbmt.2009.01.015clearance measured in a 24-hour urine collection
(24-hr CrCl) is an inexpensive, but error-prone and
inconvenient method for assessing renal function.
Glomerular filtration rate (GFR) cannot be measured
directly, but can be estimated using urinary clearance
of molecular isotopes such as 99m Tc-DTPA,
125I-iothalamate, or 51Cr-EDTA, which are investiga-
tional, costly, and not widely available, plasma clear-
ance of contrast agents such as isohexol that cannot
be used in patients with an iodine allergy, or urinary
clearance of the polysaccharide inulin, which requires
precisely timed measures of blood and urine [5-8].
There are several validated equations using differ-
ent parameters to estimate GFR, offering a very cost-
effective and rapid method to evaluate renal function.
One study has evaluated several prediction models in
pediatric BMTpatients [9]; however, there are no pub-
lications evaluating GFR equations in adult BMT
patients. The appropriateness of several GFR equa-
tions has been examined in oncology patients with
varying results [8,10-12]. In elderly ($70 years) cancer
Biol Blood Marrow Transplant 15:574-579, 2009 575Assessment of Renal Function before Autologous and Allogeneic BMTpatients with a GFR .50 mL/min, the Wright for-
mula was reported as themost accurate and least biased
calculation of GFR, compared to the more commonly
used Cockroft-Gault (CG) and Jelliffe formulas [10].
The Jelliffe formula produced the greatest positive
bias (overestimation) when used to estimate carbopla-
tin clearance in gynecologic cancer patients [11]. A
study of bladder cancer patients treated on clinical
trials demonstrated low concordance between mea-
sured 24-hr CrCl and calculated CrCl using 12 equa-
tions. There was a poor correlation between the
calculated CrCl and the ability to complete 3 cycles
of cisplatin-based chemotherapy, and the authors con-
cluded that most formulas for renal function underes-
timated the measured 24-hr CrCl [13].
The following 6 equations aremost often examined
in the oncology literature: CG, modified CG (mCG),
Modification of Diet in Renal Disease 1 (MDRD1),
MDRD2, Jelliffe, andWright [14-17].Currently, there
are no recommendations or published studies delineat-
ing the most appropriate GFR prediction equation for
screening pretransplant kidney function in the adult
BMT population. Our study objectives were to (1)
determine which of 6 GFR calculations could be uti-
lized as an estimate for renal function prior to BMT
in place of the 24-hr CrCl, and (2) determine if the
GFR predicted by any of the equations is associated
with subsequent development of moderate to severe
renal RRT.METHODS
Patients
We performed a retrospective analysis of 98 con-
secutive adult ($18 years) patients who underwent
allogeneic (n 5 48) or autologous (n 5 50) BMT
from January 2006 andApril 2007 atRoswell ParkCan-
cer Institute (RPCI). Allogeneic BMT patients re-
ceived myeloablative conditioning regimens, unless
they had compromised physical functioning, organTable 1. Models for Estimating Glomerular Filtration Rate (GFR) i
24-hr CrCl (mL/min) CrurineVurineCr1440
Cockroft-Gault (mL/min)
ð1402ageÞwe
7
Modified Cockroft-Gault (mL/min/1.73m2) ð1402ageÞwe7
MDRD1 (mL/min/1.73m2) 170 Cr-0
MDRD2 (mL/min/1.73m2) ð186 Cr-
Jelliffe (mL/min/1.73m2)
½9820:8ðage2
Wright (mL/min)
ð6580238:8ag
age indicates years; weight, kg; sex, male 5 0, female 5 1; Cr, serum creatinin
BSA 5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðheight in cm  weight in kgÞ=3600p ; race, Caucasian 5 0, other etdysfunction, older age, or had a prior autologous or
allogeneic BMT. The minimum 24-hr CrCl was 50
mL/min for myeloablative and 40 mL/min for re-
duced-intensity conditioning (RIC) regimens. Patients
who underwent BMTwith a 24-hr CrCl\40 mL/min
received an autologous BMTwith a reducedmelphalan
(Mel) dose (100-120 mg/m2). This study was reviewed
and approved by the institutional review board at
RPCI. All data have been deidentified.Data Collection
All patients had 24-hr CrCl performed as part of
their routine pre-BMT evaluation. Patient compliance
with 24-hr CrCl collection was assessed by direct
patient questioning, comparison with prior 24-hr
CrCl collections, comparison to the normal expected
creatinine excretion rate, and clinical judgment. Serum
Cr and albumin were obtained as part of a routine met-
abolic profile, drawn within 0-3 days of the 24-hr CrCl
collection. Urine collection was completed for all
patients within 30 days pre-BMT, and for most pa-
tients within 2 weeks pre-BMT. Patient height and
weight were measured in the RPCI BMT clinic 1-2
days prior to the initiation of the transplant regimen.
Age, ethnicity, and sex were collected from hospital
demographic data. The following standard formula
was used to calculate 24-hr CrCl: (Crurine  Vurine)/
(Crserum  1440 min) [5]. All urine and serum testing
was performed in a single RPCI lab. In addition,
GFR was calculated retrospectively for each patient
using 6 equations: CG, mCG, MDRD1, MDRD2,
Jelliffe, and Wright (see Table 1) [14-17].Renal RRT
Renal RRT was defined according to standard
published criteria as follows: grade 0 5 no increase
from baseline serum Cr; grade 1 5 any increase over
baseline serum Cr; grade 2 5 doubling of baseline
serumCr; grade 35 requirement of dialysis; and grade
4 5 death from renal failure [18]. Renal RRT usingn Adults
ightð120:15sexÞ
2Cr
ightð120:15sexÞ
2Cr  1:73BSA
:999  age-0:176  BUN-0:017  alb0:318  ð120:238  sexÞ  ð1þ 0:18  raceÞ
1:154  age-0:203Þ  ð120:258  sexÞ  ð1þ 0:212  raceÞ
20ÞBSAð120:1sexÞ
1:73Cr
eÞBSAð1-0:168sexÞ0:0113
Cr
e, mg/dL; V, volume, mL; alb, serum albumin; BUN, blood urea nitrogen;
hnicity 5 1.
Table 2. Patient Characteristics (n 5 98)
Patient Variables N
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a weekly basis from the start of conditioning regimen
to day 1100 post-BMT.Sex
F 48
M 50
Median (Range) age in years 48 (20-74)
Race
Caucasian 91
Other 7
Donor relation
Autologous 50
Related 17
Unrelated 31
Conditioning regimen
Myeloablative 57
Reduced Intensity 26
Nonmyeloablative 15
Conditioning regimen
Total body irradiation-based 8
No total body irradiation 90
Stem cell source
Bone marrow 12
Peripheral blood 86
Prior BMT
No 72
Yes 26
Disease
Acute leukemia 26
Hematologic disorder 8
Lymphoma 44
Myeloma/amyloidosis 16
Solid tumor 4
Median (Range) KPS at BMT 80 (50-90)
Median (Range) weight in kg 84.2 (47.9-149.8)
Median (Range) BSA 2.01 (1.48-2.76)
Median (Range) serum creatinine 0.9 (0.4-2.2)
Median (Range) albumin 4 (2-4.9)Statistical Analysis
Scatter plots with regression lines and boxplots
were constructed for visualization. Outlier patient
data was quality checked by 2 authors independently.
The Pearson correlation coefficient was used for linear
regression to compare the overall precision of calcu-
lated GFR for each of 6 equations versus measured
24-hr CrCl. The P-values for R tested the null hypoth-
esis that the slope of the regression line5 zero, that is,
that the relationship between measured CrCl and pre-
dicted GFR is random and unpredictable. Wilcoxon
signed rank test was used to examine the ability of
each prediction equation to underestimate GFR,
a measure of negative bias. Univariate analyses used
logistic regression with the dichotomous outcome:
RRT grade 2-4 versus RRT grade 0-1. All P values
were 2 sided, with P\ .05 considered statistically sig-
nificant. Multivariate analyses could not be performed
because of colinearity of the prediction equations with
the covariates. Subgroup stratification by autologous
versus allogeneic BMT and myeloma versus nonmye-
loma diagnosis was performed. All statistical analyses
were performed using SPSS 16.0 (SPSS, Inc., Chi-
cago, IL).Median (Range) blood urea nitrogen 15 (2-36)
Median (Range) measured 24hr CrCl 99.5 (36.5-288)
Median (Range) Calculated GFR—CG 107.7 (40-337)
Median (Range) Calculated GFR—ModCG 95.5 (42-262)
Median (Range) Calculated GFR—MDRD1 85.0 (37-287)
Median (Range) Calculated GFR—MDRD2 87.4 (34-283)
Median (Range) Calculated GFR—Jelliffe 92.3 (38-271)
Median (Range) Calculated GFR—Wright 109.1 (46-315)RESULTS
Comparison of Measured Creatinine Clearance
and Calculated GFR
Patient characteristics are shown in Table 2. We
compared the measured 24-hr CrCl for each patient
with GFR predicted by each of the 6 formulas using
linear regression. All 6 formulas were significantly (P
\ .0001) correlated with measured 24-hr CrCl with
correlation coefficients (R) of 0.64 (Wright), 0.63
(CG), 0.61 (mCG), 0.61 (Jeliffe), 0.54 (MDRD2),
and 0.50 (MDRD1) (see Figure 1). Because the mea-
sured 24-hr CrCl overestimates the true GFR [19],
we also examined the degree to which each prediction
equation underestimated the measured 24-hr CrCl.
MDRD2 consistently underestimated GFR in the
highest proportion of patients (66%, P\ .001), com-
pared to MDRD1 (65%, P 5 .001), Jelliffe (61%,
P 5 NS), mCG (55%, P 5 NS), Wright (34%,
P\ .001) and CG (34%, P5 .001) (see Table 3). Un-
derestimation of the measured 24-hr CrCl would
likely be most critical at the lowest range (40-70 mL/
min), where MDRD2 performed best (44% underesti-
mation), followed by mCG (31%), Jeliffe (31%),
MDRD1 (31%), CG (19%), and Wright (6%).Figure 2 depicts the percent difference between
each of the 6 formulas and the measured 24-hr CrCl
at different levels of measured 24-hr CrCl (40-70,
70-90, 90-120, and 1201 mL/min) for each of the 6
formulas. Positive values above the horizontal line in-
dicate the calculated formula overestimated the mea-
sured 24-hr CrCl; negative values indicate
underestimation. The CG model overestimated mea-
sured 24-hr CrCl at all GFR levels, whereas the
MDRD2 demonstrated the least overestimation, espe-
cially at the lower end of theGFR range (40-70 and 70-
90 mL/min). The MDRD2, MDRD1, Jelliffe, and
mCG formulas were less likely to overestimate 24-hr
CrCl when compared to the CG or Wright formulas.
Therefore, MDRD2, MDRD1, Jelliffe, and mCG are
recommended as the best formulas for underestima-
tion of GFR, especially near the transplant eligibility
threshold.
Figure 1. Scatterplots and fitted regression lines for measured creatinine clearance versus calculated glomerular filtration rate for 6 models.
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Four patients were consistent outliers in 4 or more
formulas (Patient IDs 39, 60, 92, and 97); however, they
were not excluded from any analyses. Their calculated
formulas far exceeded their measured 24-hr CrCl, and
may represent patient errors in the 24-hr CrCl collec-
tion. However, 47% of females and 80% of males were
below the normal creatinine excretion rates of 15-20
mg/kg/24 hours and 20-25 mg/kg/24 hours,
respectively, based on themeasured 24-hr CrCl collec-
tion. Surprisingly, the patients at the extreme ends of
the creatinine excretion rates were not the discordant
outliers in Figure 2. Because most BMT patients have
received prior cytotoxic therapy, the low creatinine ex-
cretion rates may represent deconditioning and lost
muscle mass during previous therapy.
Incidence and Risk Factors for Renal RRT
The incidence of renal RRT was 24%, 57%, 18%,
1%, and 0% for grades 0, 1, 2, 3, and 4, respectively.
Measured 24-hr CrCl, serum Cr, and all 6 GFR calcu-
lations were not predictive of renal RRT post-BMT.
Significant univariate predictors of grades 2-3 renal
RRT were: allogeneic BMT, RIC/nonmyeloablative
regimens, Karnofsky Performance Score (KPS) #80and pre-BMT albumin #3.7 g/dL. In allogeneic
BMT patients, BMI .35, KPS #80, and albumin
#3.8 g/dL were significantly associated with grades
2-3 renal RRT, whereas in autologous BMT patients,
baseline serum Cr$1.1 was the only significant factor.
As noted in theMethods section, multivariate analyses
could not be performed because of colinearity of the
prediction equations with the covariates.
Interestingly, patients who received RIC or non-
myeloablative conditioning had an increased risk of
grade 2-3 renal RRT. Compared to myeloablative reg-
imens, patients who received RIC or nonmyeloablative
conditioning were more likely to be treated for acute
leukemia or a hematologic disorder (54% versus
24%, P 5 .0009), have a lower KPS (41% versus 15%
with KPS\80, P5 .003), have an unrelated allogeneic
donor (66% versus 7%, P\ .0001), and have a prior
BMT (54% versus 7%, P\ .0001). Therefore, patients
who received these lower intensity regimens had char-
acteristics related to increased risk of renal toxicity.DISCUSSION
The Cockroft-Gault formula is the most com-
monly studied equation, and was originally developed
Table 3. Difference between Measured Creatinine Clearance and Calculated Glomerular Filtration Rate
Measured Creatinine Clearance (mL/min)
40-70 (n 5 16) 70-90 (n 5 21) 90-120 (n 5 31) 120+ (n 5 30) Total (n 5 98)
CG median (range) % difference1 21.9 (216.4106.2) 22.3 (217.298.8) 14.4 (238.1201.0) 3.2 (239.597.7) 14.0 (239.5201.0)
% underestimation2 19%** 29%** 35%* 43% 34%***
mCG median (range) % difference1 14.0 (219.893.5) 15.2 (242.559.6) 23.9 (248.2101.1) 217.2 (253.074.5) 24.0 (253.0101.1)
% underestimation2 31%* 29%* 55% 87%*** 55%
MDRD1 median (range) % difference1 9.6 (220.994.7) 3.8 (255.343.1) 217.7 (264.261.6) 233.4 (256.591.4) 214.8 (264.294.7)
% underestimation2 31%* 38% 74%** 93%*** 65%**
MDRD2 median (range) % difference1 8.3 (227.2105.5) 7.0 (259.256.2) 212.3 (262.562.2) 232.2 (257.288.9) 212.0 (262.5105.5)
% underestimation2 44% 43% 68%* 93%*** 66%**
Jelliffe median (range) % difference1 9.8 (222.167.3) 11.1 (241.657.1) 26.3 (250.496.4) 221.6 (254.980.5) 27.1 (254.996.4)
% underestimation2 31% 33%* 68% 90%*** 61%
Wright median (range) % difference1 25.6 (20.8111.4) 27.6 (228.483.7) 6.8 (237.5122.3) 25.9 (243.1110.0) 7.9 (243.1122.3)
% underestimation2 6%*** 10%*** 26%* 73% 34%***
CG indicates Cockroft-Gault model; mCG, modified Cockroft-Gault model; MDRD, Modification of Diet in Renal Disease.
* is <.05; ** is <.01; *** is <.001.
1Positive values indicate the calculatedGFR is greater than themeasured 24hr CrCl; negative values indicate the calculated GFR is less than themeasured
24-hr CrCl.
2Asterisk denotes statistically significant difference from measured 24hr CrCl using Wilcoxon signed-rank test
578 Biol Blood Marrow Transplant 15:574-579, 2009T. Hahn et al.to predict the 24-hr CrCl in a limited sample (\250) of
Caucasian males [5,14]. The modified CG, Jelliffe, and
Wright formulas were developed to account for body
size and sex. The MDRD1 and MDRD2 formulas
have the advantage of being developed to predict
GFR measured by urinary clearance of 125I-iothala-
mate in a large (.1000) sample of both males and fe-
males and European- and African-American
participants. The MDRD2 formula has been validated
in large and varied populations [5,6]. Therefore, the
MDRD formula is recommended in adults by theFigure 2. Boxplot of percent difference between measured creatinine cleara
sured creatinine clearance. Please note that the bar in color denotes the 25% t
a short black line in the middle; error bars denote the range of percent differKidney Disease Outcomes Quality Initiative (K/DO-
QITM) guidelines of the National Kidney Foundation
because it is the least biased and most accurate equa-
tion for GFR estimation [5].
However, the MDRD2 calculation is not as
straightforward and easy to memorize as other formu-
las. Online resources exist in which the user is promp-
ted to enter laboratory and demographic data
necessary for the MDRD calculation and are then
provided with the patient’s GFR. There are several
freely accessible Web sites (www.kdoqi.org ornce and calculated glomerular filtration rate at different ranges of mea-
o 75% percentile of percent difference, with median (50% percentile) as
ence; asterisks denote outliers with the patient ID.
Biol Blood Marrow Transplant 15:574-579, 2009 579Assessment of Renal Function before Autologous and Allogeneic BMThttp://www.nkdep.nih.gov/professionals/gfr_calcula-
tors/index.htm) or the equation can be easily pro-
grammed or imported into calculators, PDAs, or
laboratory systems.
We found no correlation between the pretrans-
plant GFR estimation from any of the 6 equations or
the measured CrCl and the development of posttrans-
plant moderate to severe (grade 2-3) renal RRT.
Because of the relatively low incidence of severe grade
3 renal toxicity (1%), a very large cohort would be nec-
essary to examine a correlationwith baselineGFR.Our
results suggest a lower GFR threshold may be accept-
able for BMT because of the relatively low incidence
of severe renal toxicity observed. Larger analyses of
patients undergoing BMT at a lower GFR threshold
may better define subgroups at risk for renal RRT.
In our retrospective analysis, we identify MDRD2
as the most conservative equation for determining
GFR as it most likely underestimates kidney function.
However, the mCG, Jelliffe, and MDRD1 formulas
also underestimate renal function and would be
reasonable alternative calculations of 24-hr CrCl.
The mCG and Jelliffe formulas require height and
weight for BSA calculation in addition to the same lab-
oratory and demographic data as the CG formula.
MDRD1 requires additional laboratory data for blood
urea nitrogen and albumin. Thus, we can recommend
using the MDRD2, mCG, Jelliffe, and MDRD1 for-
mulas for conservative estimates of renal function
without the need to perform a 24-hr CrCl.ACKNOWLEDGMENTS
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